C–H Bond Arylations and Benzylations on Oxazol(in)es with a Palladium Catalyst of a Secondary Phosphine Oxide
摘要:
An air-stable, well-defined palladium complex derived from secondary phosphine oxide (SPO) (1-Ad)(2)P(O)H enabled efficient C-H bond functionalizations with ample scope, which set the stage for direct arylations and benzylations of (benz)oxazoles, as well as unprecedented palladium-catalyzed C-H bond arylations on nonaromatic oxazolines.
This invention relates to a process for preparation of the compounds of lignan series in a regioselective manner. This invention provide a process for preparing a compound of the formula (I): which process is characterized by that a lactone compound represented by the formula (II) is allowed to react with a compound of the formula: R.sup.7 Cl in the presence of a base, then the resulting compound is subjected to addition reaction with an acetylenic compound of the formula (III), then the resulting compound is reduced; in which R.sup.1 is alkyl, cycloalkyl, cycloalkyl lower alkyl, or aralkyl and the like; R.sup.2 and R.sup.3 each is lower alkoxy and the like; R.sup.4 is lower alkoxy or hydrogen; and R.sup.5 and R.sup.6 each is lower alkyl; and R.sup.7 is tri(lower alkyl)silyl. ##STR1##
LIGNAN ANALOG, PRODUCTION THEREOF, AND HYPOLIPIDEMIC DRUG
申请人:SHIONOGI & CO., LTD.
公开号:EP0597107A1
公开(公告)日:1994-05-18
A hypolipidemic drug which has a potent activity of reducing LDL and VLDL cholesterols which are thought to be a risk factor causative of arteriosclerosis among total blood cholesterols and is excellent in the antioxidant activity on LDL; and a compound represented by general formula (I) and a pharmaceutically acceptable salt thereof, wherein R¹ represents optionally substituted lower alkyl, cycloalkyl, cycloalkylated lower alkyl, aryl or aralkyl; R² represents - COOR', lower alkyl or halogenated lower alkyl, or aternatively R¹ and R² form together with the adjacent carbonyl group a cyclohexanone ring represented by formula (II); R³ represents optionally substituted phenyl; and ring A represents an optionally substituted benzene ring or an optionally substituted heterocycle containing either sulfur or oxygen.
一种降血脂药物,具有降低低密度脂蛋白和超低密度脂蛋白胆固醇的强效活性,而低密度脂蛋白和超低密度脂蛋白胆固醇被认为是血液总胆固醇中导致动脉硬化的危险因素,并且对低密度脂蛋白具有极佳的抗氧化活性;以及通式(I)代表的化合物及其药学上可接受的盐,其中 R¹ 代表任选取代的低级烷基、环烷基、环烷基化低级烷基、芳基或芳烷基;R²代表-COOR'、低级烷基或卤代低级烷基,或者R¹和R²与相邻的羰基一起形成由式(II)表示的环己酮环;R³代表任选取代的苯基;环 A 代表任选取代的苯环或任选取代的含硫或氧的杂环。
PROCESS FOR PRODUCING LIGNAN COMPOUND
申请人:SHIONOGI & CO., LTD.
公开号:EP0646570A1
公开(公告)日:1995-04-05
A process for regioselectively producing a lignan compound of general formula (I) by reacting a lactone compound of general formula (II) with a compound of the formula: R⁷Cl (R⁷ being a tri(lower alkyl)silyl group) in the presence of a base, effecting the addition reaction of an acetylene compound of general formula (III) with the resultant compound, and reducing the product. In said formulas R¹ represents alkyl, cycloalkyl, cycloalkyl-lower alkyl, aralkyl, etc.: R² and R³ each represent lower alkoxy, etc.; R⁴ represents lower alkoxy or hydrogen; and R⁵ and R⁶ each represent lower alkyl.